PE20231385A1 - Composiciones de vacunas multivalentes y usos de las mismas - Google Patents
Composiciones de vacunas multivalentes y usos de las mismasInfo
- Publication number
- PE20231385A1 PE20231385A1 PE2023001175A PE2023001175A PE20231385A1 PE 20231385 A1 PE20231385 A1 PE 20231385A1 PE 2023001175 A PE2023001175 A PE 2023001175A PE 2023001175 A PE2023001175 A PE 2023001175A PE 20231385 A1 PE20231385 A1 PE 20231385A1
- Authority
- PE
- Peru
- Prior art keywords
- antigen
- infections
- coli
- expec
- concentration
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 229940031348 multivalent vaccine Drugs 0.000 title 1
- 239000000427 antigen Substances 0.000 abstract 6
- 102000036639 antigens Human genes 0.000 abstract 6
- 108091007433 antigens Proteins 0.000 abstract 6
- 150000004676 glycans Chemical class 0.000 abstract 4
- 229920001282 polysaccharide Polymers 0.000 abstract 4
- 239000005017 polysaccharide Substances 0.000 abstract 4
- 241000588724 Escherichia coli Species 0.000 abstract 3
- 208000019206 urinary tract infection Diseases 0.000 abstract 2
- 206010056519 Abdominal infection Diseases 0.000 abstract 1
- 206010007882 Cellulitis Diseases 0.000 abstract 1
- 208000008745 Healthcare-Associated Pneumonia Diseases 0.000 abstract 1
- 206010058780 Meningitis neonatal Diseases 0.000 abstract 1
- 206010031252 Osteomyelitis Diseases 0.000 abstract 1
- 206010058674 Pelvic Infection Diseases 0.000 abstract 1
- 206010035664 Pneumonia Diseases 0.000 abstract 1
- 208000031650 Surgical Wound Infection Diseases 0.000 abstract 1
- 206010048038 Wound infection Diseases 0.000 abstract 1
- 230000003187 abdominal effect Effects 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 238000002255 vaccination Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/739—Lipopolysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0258—Escherichia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55583—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063079734P | 2020-09-17 | 2020-09-17 | |
| EP21154782 | 2021-02-02 | ||
| US202163191471P | 2021-05-21 | 2021-05-21 | |
| PCT/IB2021/058485 WO2022058945A1 (en) | 2020-09-17 | 2021-09-17 | Multivalent vaccine compositions and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20231385A1 true PE20231385A1 (es) | 2023-09-12 |
Family
ID=77801756
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2023001175A PE20231385A1 (es) | 2020-09-17 | 2021-09-17 | Composiciones de vacunas multivalentes y usos de las mismas |
Country Status (18)
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL286467B1 (en) | 2019-03-18 | 2025-10-01 | Janssen Pharmaceuticals Inc | Methods for producing bioconjugates of E. COLI O-antigen polysaccharides, preparations thereof and methods for using them |
| UY38616A (es) | 2019-03-18 | 2020-09-30 | Janssen Pharmaceuticals Inc | Bioconjugados de polisacáridos del antígeno-o de e. coli y métodos de producción y de uso de los mismos. |
| AR131046A1 (es) * | 2022-11-15 | 2025-02-12 | Janssen Pharmaceuticals Inc | Composiciones de vacunas multivalentes y sus usos |
| WO2024146325A1 (zh) * | 2023-01-06 | 2024-07-11 | 中国人民解放军军事科学院军事医学研究院 | 用于生产抗原多糖-载体蛋白生物偶联产物的工程菌及其应用 |
| GB202302579D0 (en) * | 2023-02-23 | 2023-04-12 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
| WO2024186262A1 (en) * | 2023-03-03 | 2024-09-12 | Agency For Science, Technology And Research | Use of o-antigens for treating bacterial infections |
| EP4478050A1 (en) | 2023-06-12 | 2024-12-18 | Janssen Pharmaceuticals, Inc. | Method for quantifying bound acetate in glycoconjugates |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3700612A (en) | 1971-06-23 | 1972-10-24 | Tenneco Chem | Aqueous surface-coating compositions containing hydroxyalkyl ethers of galactomannan gums as thickeners |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8422653D0 (en) | 1984-09-07 | 1984-10-10 | Technology Licence Co Ltd | Monoclonal antibodies |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| US5370872A (en) | 1991-08-12 | 1994-12-06 | Swiss Serum And Vaccine Institute Berne | Escherichia coliO-polysaccharide-protein conjugate vaccine |
| NZ249704A (en) | 1992-02-11 | 1996-11-26 | Jackson H M Found Military Med | A two carrier immunogenic construct comprising a 70+ kd molecule conjugated to at least 1 t-dependent antigen, preparation, compositions containing the construct |
| SK279188B6 (sk) | 1992-06-25 | 1998-07-08 | Smithkline Beecham Biologicals S.A. | Vakcínová kompozícia spôsob jej prípravy a použiti |
| PT616034E (pt) | 1993-03-05 | 2005-02-28 | Wyeth Corp | Plasmideo para a producao de proteina crm e toxina da difteria |
| ES2210262T3 (es) | 1993-09-22 | 2004-07-01 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Procedimiento que permite activar un glucido soluble con la ayuda de nuevos reactivos cianilantes para producir estructuras inmunogenas. |
| AUPM399594A0 (en) | 1994-02-21 | 1994-03-17 | Csl Limited | Antigenic preparation for treatment or prevention of helicobacter infection |
| FI102976B (fi) | 1994-02-28 | 1999-03-31 | Valtion Teknillinen | Menetelmä lisäkeittokemikaalien tuottamiseksi sekä käyttämiseksi sulfa attiselluloosaprosessissa |
| WO1996029094A1 (en) | 1995-03-22 | 1996-09-26 | Andrew Lees | Producing immunogenic constructs using soluble carbohydrates activated via organic cyanylating reagents |
| US6299881B1 (en) | 1997-03-24 | 2001-10-09 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts |
| TR199902437T2 (xx) | 1997-04-01 | 2000-01-21 | Corixa Corporation | Monofosforil lipid A'ya ait sulu im�nolojik adjuvant terkipleri. |
| US6491919B2 (en) | 1997-04-01 | 2002-12-10 | Corixa Corporation | Aqueous immunologic adjuvant compostions of monophosphoryl lipid A |
| US6858211B1 (en) | 1998-07-20 | 2005-02-22 | The United States Of America As Represented By The Department Of Health And Human Services | Vaccines against Escherichia coli O157 infection |
| DK1126876T3 (da) | 1998-10-16 | 2007-07-02 | Glaxosmithkline Biolog Sa | Adjuvanssystemer og vacciner |
| AU5162201A (en) | 2000-04-13 | 2001-10-30 | Corixa Corporation | Immunostimulant compositions comprising an aminoalkyl glucosaminide phosphate and qs-21 |
| AU2001253568A1 (en) | 2000-04-18 | 2001-10-30 | Dan C. Deborde | Lipopolysaccharide-conjugate vaccine for sepsis treatment |
| RU2189253C1 (ru) | 2001-04-09 | 2002-09-20 | Государственный научный центр прикладной микробиологии | Диагностикум для идентификации escherichia coli o157 : h7 и способ его получения |
| US6676958B2 (en) | 2001-06-19 | 2004-01-13 | Advanced Bioadjuvants, Llc | Adjuvant composition for mucosal and injection delivered vaccines |
| US20040110226A1 (en) | 2002-03-01 | 2004-06-10 | Xencor | Antibody optimization |
| IL163806A0 (en) | 2002-03-07 | 2005-12-18 | Eidgenoess Tech Hochschule | System and method for the production of recombinant glycosylated proteins in a prokaryotic host |
| AU2003901008A0 (en) | 2003-03-04 | 2003-03-20 | Anadis Ltd | Composition for the treatment and prevention of bacterial infections |
| CN1324134C (zh) | 2003-12-22 | 2007-07-04 | 南开大学 | 对大肠杆菌o81型的o－抗原特异的核苷酸 |
| WO2005095450A2 (en) | 2004-03-30 | 2005-10-13 | Nsgene A/S | Therapeutic use of a growth factor, nsg33 |
| CN101360831B (zh) | 2005-05-11 | 2013-07-10 | Eth苏黎世公司 | 来自原核细胞的重组n-糖基化蛋白 |
| TWI457133B (zh) | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | 新穎組合物 |
| US8063063B2 (en) | 2006-03-23 | 2011-11-22 | Novartis Ag | Immunopotentiating compounds |
| ES2536426T3 (es) | 2006-03-23 | 2015-05-25 | Novartis Ag | Compuestos de imidazoquinoxalina como inmunomoduladores |
| JP4791866B2 (ja) | 2006-03-24 | 2011-10-12 | 国立大学法人秋田大学 | 下痢原性大腸菌感染症の判別に用いられる固相等 |
| US8877688B2 (en) | 2007-09-14 | 2014-11-04 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
| EP2193146B1 (en) | 2007-09-14 | 2016-05-25 | Adimab, LLC | Rationally designed, synthetic antibody libraries and uses therefor |
| EP2242505A4 (en) | 2008-01-08 | 2012-03-07 | Biogenerix Ag | GLYCOCONJUGATION OF POLYPEPTIDES USING OLIGOSACCHARYLTRANSFERASES |
| SG10201400320TA (en) | 2008-02-20 | 2014-05-29 | Glycovaxyn Ag | Bioconjugates made from recombinant n-glycosylated proteins from procaryotic cells |
| EP3461840A1 (en) | 2009-04-27 | 2019-04-03 | Immuron Limited | Anti-lps enriched immunoglobulin preparation for use in treatment and/or prophylaxis of non alcoholic steatohepatitis |
| BRPI1011072B1 (pt) | 2009-06-05 | 2021-09-28 | Infectious Disease Research Institute | Composto de gla, composições de vacina e farmacêutica compreendendo dito composto, bem como uso dos mesmos para estimular, induzir ou acentuar uma resposta imune em um indivíduo |
| WO2011062615A1 (en) | 2009-11-19 | 2011-05-26 | Glycovaxyn Ag | Biosynthetic system that produces immunogenic polysaccharides in prokaryotic cells |
| AU2011279073B2 (en) | 2010-07-16 | 2016-06-09 | Adimab, Llc | Antibody libraries |
| JP2014502595A (ja) | 2010-12-10 | 2014-02-03 | メルク・シャープ・アンド・ドーム・コーポレーション | 免疫原性組成物の撹拌誘導凝集を緩和する新規な製剤 |
| CA2847621A1 (en) | 2011-09-06 | 2013-03-14 | Glycovaxyn Ag | Bioconjugate vaccines made in prokaryotic cells |
| US9932598B2 (en) | 2012-08-02 | 2018-04-03 | The Regents Of The University Of California | Metabolic engineering of microbial organisms |
| MY167579A (en) | 2012-08-16 | 2018-09-20 | Pfizer | Glycoconjugation processes and compositions |
| HK1212249A1 (en) | 2012-09-10 | 2016-06-10 | Glycovaxyn Ag | Bioconjugates comprising modified antigens and uses thereof |
| EP2906681B1 (en) | 2012-10-12 | 2019-01-09 | GlaxoSmithKline Biologicals S.A. | Methods of host cell modification |
| ES2713166T3 (es) | 2012-11-07 | 2019-05-20 | Glaxosmithkline Biologicals Sa | Producción de vacuna recombinante en E. coli mediante conjugación enzimática |
| PT3363806T (pt) | 2012-12-20 | 2022-12-16 | Pfizer | Processo de glicoconjugação |
| EP2938363B1 (en) | 2012-12-27 | 2019-08-21 | GlaxoSmithKline Biologicals S.A. | Methods and compositions relating to crm197 |
| IL273685B2 (en) | 2013-01-17 | 2023-10-01 | X4 Pharmaceuticals Austria Gmbh | Immunogens and vaccines containing O25b antigens |
| HUE046942T2 (hu) | 2013-05-18 | 2020-04-28 | Aduro Biotech Inc | Készítmények és eljárások "Interferongén-stimulátor"-tól függõ jelátvitel aktiválására |
| CN103495161B (zh) | 2013-10-08 | 2019-06-18 | 江苏康泰生物医学技术有限公司 | 一种多元肺炎球菌荚膜多糖-蛋白质结合物的混合物及其制备方法 |
| BR112016007727A8 (pt) | 2013-10-11 | 2018-01-30 | Glycovaxyn Ag | célula hospedeira, e, método para produzir uma proteína n-glicosilada. |
| EP2870974A1 (en) | 2013-11-08 | 2015-05-13 | Novartis AG | Salmonella conjugate vaccines |
| JP2016540764A (ja) | 2013-12-04 | 2016-12-28 | グリコヴァキシン アーゲー | 大腸菌で合成された糖タンパク質ワクチンによる黄色ブドウ球菌感染の予防 |
| CA2935532A1 (en) | 2014-02-06 | 2015-08-13 | Arsanis Biosciences Gmbh | E. coli specific antibody sequences |
| LT3110441T (lt) * | 2014-02-24 | 2024-04-25 | Glaxosmithkline Biologicals S.A. | Naujas polisacharidas ir jo panaudojimas |
| LT3131577T (lt) | 2014-04-17 | 2020-07-27 | Glaxosmithkline Biologicals S.A. | Modifikuotos ląstelės-šeimininkės ir jų naudojimas |
| CN105695497B (zh) | 2014-11-27 | 2019-09-24 | 中国人民解放军军事医学科学院生物工程研究所 | 一种细菌多糖修饰的重组融合蛋白的制备方法及其应用 |
| HUE057726T2 (hu) | 2014-12-30 | 2022-06-28 | Glaxosmithkline Biologicals Sa | Fehérje glikozilálására szolgáló készítmények és módszerek |
| TWI715617B (zh) | 2015-08-24 | 2021-01-11 | 比利時商葛蘭素史密斯克藍生物品公司 | 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物 |
| GB201518668D0 (en) | 2015-10-21 | 2015-12-02 | Glaxosmithkline Biolog Sa | Immunogenic Comosition |
| GB201610599D0 (en) | 2016-06-17 | 2016-08-03 | Glaxosmithkline Biologicals Sa | Immunogenic Composition |
| AR109621A1 (es) | 2016-10-24 | 2018-12-26 | Janssen Pharmaceuticals Inc | Formulaciones de vacunas contra glucoconjugados de expec |
| GB201711635D0 (en) | 2017-07-19 | 2017-08-30 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
| US11260119B2 (en) | 2018-08-24 | 2022-03-01 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
| JP7551618B2 (ja) | 2018-12-12 | 2024-09-17 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | Ｏ－結合型グリコシル化のための修飾キャリアタンパク質 |
| IL286467B1 (en) * | 2019-03-18 | 2025-10-01 | Janssen Pharmaceuticals Inc | Methods for producing bioconjugates of E. COLI O-antigen polysaccharides, preparations thereof and methods for using them |
| UY38616A (es) | 2019-03-18 | 2020-09-30 | Janssen Pharmaceuticals Inc | Bioconjugados de polisacáridos del antígeno-o de e. coli y métodos de producción y de uso de los mismos. |
| FR3098334B1 (fr) | 2019-07-05 | 2021-07-23 | Airbus Operations Sas | Procédé et système de surveillance d’un état de conscience d’un opérateur dans un poste de pilotage d’un aéronef |
| IL307247A (en) * | 2021-04-01 | 2023-11-01 | Janssen Pharmaceuticals Inc | Production of E. Coli O18 bioconjugates |
-
2021
- 2021-09-17 IL IL301248A patent/IL301248B2/en unknown
- 2021-09-17 JP JP2023517329A patent/JP7481585B2/ja active Active
- 2021-09-17 CN CN202411689651.6A patent/CN119454928A/zh active Pending
- 2021-09-17 UY UY0001039428A patent/UY39428A/es unknown
- 2021-09-17 AU AU2021342797A patent/AU2021342797B2/en active Active
- 2021-09-17 CN CN202411689646.5A patent/CN119454927A/zh active Pending
- 2021-09-17 EP EP21772844.3A patent/EP4213870A1/en active Pending
- 2021-09-17 IL IL308201A patent/IL308201A/en unknown
- 2021-09-17 MX MX2023003169A patent/MX2023003169A/es unknown
- 2021-09-17 WO PCT/IB2021/058485 patent/WO2022058945A1/en not_active Ceased
- 2021-09-17 US US17/478,584 patent/US12233118B2/en active Active
- 2021-09-17 CN CN202180049038.6A patent/CN115803087B/zh active Active
- 2021-09-17 BR BR112023004819A patent/BR112023004819A2/pt unknown
- 2021-09-17 PE PE2023001175A patent/PE20231385A1/es unknown
- 2021-09-17 CA CA3190820A patent/CA3190820C/en active Active
- 2021-09-17 PH PH1/2023/550020A patent/PH12023550020A1/en unknown
- 2021-09-17 TW TW110135002A patent/TW202227128A/zh unknown
- 2021-09-17 KR KR1020237006127A patent/KR20230043157A/ko active Pending
-
2023
- 2023-02-27 CO CONC2023/0002114A patent/CO2023002114A2/es unknown
- 2023-03-15 CL CL2023000740A patent/CL2023000740A1/es unknown
- 2023-03-17 EC ECSENADI202319295A patent/ECSP23019295A/es unknown
-
2024
- 2024-04-25 JP JP2024071024A patent/JP2024099716A/ja active Pending
-
2025
- 2025-01-16 US US19/025,061 patent/US20250222088A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230043157A (ko) | 2023-03-30 |
| WO2022058945A1 (en) | 2022-03-24 |
| IL308201A (en) | 2024-01-01 |
| CL2023000740A1 (es) | 2023-09-29 |
| CA3190820A1 (en) | 2022-03-24 |
| CN115803087A (zh) | 2023-03-14 |
| BR112023004819A2 (pt) | 2023-04-18 |
| CN119454928A (zh) | 2025-02-18 |
| ECSP23019295A (es) | 2023-04-28 |
| AU2021342797B2 (en) | 2024-02-08 |
| JP7481585B2 (ja) | 2024-05-10 |
| MX2023003169A (es) | 2023-03-27 |
| PH12023550020A1 (en) | 2024-03-11 |
| IL301248B2 (en) | 2024-04-01 |
| US20220088165A1 (en) | 2022-03-24 |
| CO2023002114A2 (es) | 2023-03-07 |
| JP2023539943A (ja) | 2023-09-20 |
| US20250222088A1 (en) | 2025-07-10 |
| UY39428A (es) | 2022-03-31 |
| TW202227128A (zh) | 2022-07-16 |
| AU2021342797A1 (en) | 2023-02-16 |
| CA3190820C (en) | 2024-11-19 |
| EP4213870A1 (en) | 2023-07-26 |
| US12233118B2 (en) | 2025-02-25 |
| IL301248A (en) | 2023-05-01 |
| CN119454927A (zh) | 2025-02-18 |
| IL301248B1 (en) | 2023-12-01 |
| JP2024099716A (ja) | 2024-07-25 |
| CN115803087B (zh) | 2024-12-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20231385A1 (es) | Composiciones de vacunas multivalentes y usos de las mismas | |
| Hatz et al. | Safety and immunogenicity of a candidate bioconjugate vaccine against Shigella dysenteriae type 1 administered to healthy adults: A single blind, partially randomized Phase I study | |
| Baumann et al. | Recombinant OprF–OprI as a vaccine against Pseudomonas aeruginosa infections | |
| Thomsen et al. | Anti-Pseudomonas aeruginosa IgY antibodies augment bacterial clearance in a murine pneumonia model | |
| AR100859A1 (es) | Polisacáridos y sus usos | |
| CO2019007982A2 (es) | Composiciones de neisseria meningitidis y métodos respectivos | |
| ES2495744T3 (es) | Glucanos con adyuvante | |
| CY1111916T1 (el) | Εμβολιο ζωντανου εξασθενημενου ροταϊου για χορηγηση απο του στοματος | |
| RU2016127123A (ru) | Капсульные полисахариды Streptococcus pneumoniae и их конъюгаты | |
| Khim et al. | Deimmunization of flagellin for repeated administration as a vaccine adjuvant | |
| ES2599908T3 (es) | Glucanos beta-1,3-enlazados conjugados | |
| Zeng et al. | A totally synthetic lipopeptide-based self-adjuvanting vaccine induces neutralizing antibodies against heat-stable enterotoxin from enterotoxigenic Escherichia coli | |
| Han et al. | A bivalent vaccine derived from attenuated Salmonella expressing O-antigen polysaccharide provides protection against avian pathogenic Escherichia coli O1 and O2 infection | |
| Upadhyay et al. | A polyvalent multiepitope protein cross-protects against Vibrio cholerae infection in rabbit colonization and passive protection models | |
| ES2537019T3 (es) | Sacáridos Vi conjugados | |
| Souci et al. | Intranasal inoculations of naked or PLGA-PEI nanovectored DNA vaccine induce systemic and mucosal antibodies in pigs: A feasibility study | |
| Marshall et al. | Safety and immunogenicity of a booster dose of a 3-antigen Staphylococcus aureus vaccine (SA3Ag) in healthy adults: A randomized phase 1 study | |
| BR112022004921A2 (pt) | Composições para neisseria meningitidis e métodos das mesmas | |
| Patel et al. | Intranasal immunization with an archaeal lipid mucosal vaccine adjuvant and delivery formulation protects against a respiratory pathogen challenge | |
| AR123545A1 (es) | Composiciones de vacunas multivalentes y usos de las mismas | |
| Mansouri et al. | Enhanced immunoprotection against Acinetobacter baumannii infection: Synergistic effects of Bap and BauA in a murine model | |
| Mukherjee et al. | Studies on formulation of a combination heat killed immunogen from diarrheagenic Escherichia coli and Vibrio cholerae in RITARD model | |
| JP2013516396A (ja) | ロドコッカス・エクイに対する動物保護用組成物のための投与経路 | |
| Espinosa-de los Monteros et al. | Reemplazo de serotipos de Streptococcus pneumoniae en niños con vacuna conjugada antineumocóccica 7V en México | |
| JOP20200214A1 (ar) | تركيبات مولدة للمناعة ضد الأمراض المعوية وطرق لتحضيرها |